CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory

Core Insights - CROSSJECT has made significant progress in the development and regulatory preparation of ZEPIZURE®, an injectable for managing epileptic seizures, with a focus on its proprietary ZENEO® needle-free auto-injector technology [1][5][6] Financial Performance - For the financial year ending December 31, 2025, CROSSJECT reported operating revenue of €14.9 million, a 12.2% increase from €13.3 million in 2024, primarily driven by BARDA invoicing which rose to €12.1 million from €8.2 million [3][14] - Operating expenses increased slightly to €26.5 million from €26.2 million in 2024, resulting in an operating loss of €11.6 million, an improvement from a loss of €13.0 million in 2024 [15][16] - The net loss for 2025 was €10.4 million, improved from €12.8 million in 2024, reflecting better revenue growth and disciplined expenditure management [16] Funding and Financial Structure - CROSSJECT received increased funding from BARDA, totaling $43.3 million, which supports regulatory and manufacturing activities [2][8] - The company reduced its bank debt by €2.7 million, with borrowings from credit institutions decreasing to €10.2 million from €12.9 million at the end of 2024 [4][18] - As of December 31, 2025, CROSSJECT had available cash of €5.1 million, supplemented by a €2.8 million research tax credit receivable, totaling €7.9 million [3][20] Regulatory and Operational Developments - In 2025, CROSSJECT achieved satisfactory stability results for ZEPIZURE® and produced additional validation batches, preparing for regulatory submissions [6][9] - The company is actively pursuing an Emergency Use Authorization (EUA) application in coordination with BARDA, aiming for commercial deliveries in 2026 and U.S. commercialization in 2027 [5][23] Strategic Direction - CROSSJECT is focusing on the development of its ZENEO® platform, including ZEPIZURE® Junior for pediatric use, and estimates the commercial potential of its emergency medicines portfolio could reach annual peak sales of around €1 billion [10][9] - The company has strengthened its governance and market visibility, with new coverage initiated by financial institutions and preparations for direct commercialization in the U.S. [12][13]